GeoVax Labs, Inc. raises $3.0M Private Placement (United States, May 2026)
Find the investors funding Health Private Placement rounds
326,000+ VC, angel and family-office profiles — direct emails, check sizes and stage filters.
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules - TradingView
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancers. The company is notable for its expedited regulatory pathway for its GEO-MVA vaccine targeting mpox and smallpox, with plans for a pivotal Phase 3 clinical trial in 2026.
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules TradingView
| Sep 10, 2026 | Positron AI | $875.0M | Series C | United States |
| Sep 10, 2026 | Socure | $156.0M | — | United States |
| Sep 10, 2026 | Celero | $275.0M | Series C | United States |
| Sep 09, 2026 | Harmoni | $10.0M | — | United States |
20,829 investors back startups in United States
You just read who funded GeoVax Labs, Inc.. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.